Aurinia Pharmaceuticals financials
$16.42−0.61%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.2M | $77.7M | $77.1M | $73.5M | $70.0M | $62.5M | $59.9M | $67.8M | $57.2M | $50.3M | $45.1M | $54.5M |
| Gross profit | $76.7M | $71.2M | $68.3M | $65.3M | $62.9M | $53.9M | $54.3M | $61.7M | $48.3M | $42.6M | $39.7M | $47.7M |
| Gross margin | 92.1% | 91.6% | 88.6% | 88.9% | 89.8% | 86.3% | 90.7% | 91.1% | 84.4% | 84.6% | 88.0% | 87.6% |
| Operating income | $46.3M | $41.4M | $18.6M | $30.7M | $20.1M | $21.8M | -$1.8M | $16.3M | -$1.5M | -$17.4M | -$29.7M | -$16.3M |
| Net income | $37.4M | $34.4M | $210.8M | $31.6M | $21.5M | $23.3M | $1.4M | $14.3M | $717.0K | -$10.7M | -$26.9M | -$13.4M |
| Net margin | 45.0% | 44.2% | 273.4% | 42.9% | 30.7% | 37.4% | 2.4% | 21.2% | 1.3% | −21.4% | −59.6% | −24.7% |
| Diluted EPS | $0.28 | $0.25 | $1.53 | $0.23 | $0.16 | $0.16 | $0.01 | $0.10 | $0.01 | $-0.07 | $-0.19 | $-0.09 |
| EBITDA | $51.2M | $46.2M | $23.5M | $35.5M | $25.1M | $28.2M | $18.4M | $21.2M | $4.4M | -$5.8M | -$29.7M | -$11.0M |
| Operating cash flow | $52.6M | $32.6M | $45.7M | $44.4M | $44.2M | $1.3M | $30.1M | $17.0M | $15.8M | -$18.6M | $14.3M | -$13.3M |
| Free cash flow | $52.6M | $32.5M | $45.6M | $44.4M | $44.1M | $1.3M | $30.1M | $16.9M | $15.7M | -$18.6M | $14.0M | -$13.4M |
| Diluted shares | 133.5M | 137.6M | 138.1M | 136.0M | 137.5M | 143.2M | 151.0M | 145.7M | 144.1M | 144.0M | 144.7M | 142.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $179.8M | $41.0M | $80.2M | $73.2M | $53.0M | $66.4M |
| Short-term investments | $263.3M | $337.8M | $317.8M | $278.6M | $262.1M | $246.5M |
| Total debt | $60.4M | $64.7M | $68.8M | $72.0M | $75.4M | $71.3M |
| Total assets | $792.3M | $724.0M | $751.6M | $527.5M | $502.6M | $504.9M |
| Total liabilities | $177.4M | $156.4M | $170.3M | $161.8M | $167.3M | $154.7M |
| Shareholders' equity | $614.9M | $567.6M | $581.3M | $365.8M | $335.3M | $350.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology